28-Mar-2024
No headlines found.
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
Globe Newswire (Mon, 25-Mar 8:00 AM ET)
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
Globe Newswire (Tue, 19-Mar 9:49 PM ET)
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
Globe Newswire (Tue, 19-Mar 4:01 PM ET)
Globe Newswire (Thu, 14-Mar 5:23 PM ET)
Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Globe Newswire (Tue, 5-Mar 5:05 PM ET)
Globe Newswire (Wed, 21-Feb 8:00 AM ET)
Globe Newswire (Thu, 15-Feb 8:00 AM ET)
Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference
Globe Newswire (Tue, 30-Jan 8:00 AM ET)
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
Aquestive Therapeutics trades on the NASDAQ stock market under the symbol AQST.
As of March 28, 2024, AQST stock price climbed to $4.26 with 6,867,304 million shares trading.
AQST has a beta of 0.84, meaning it tends to be less sensitive to market movements. AQST has a correlation of 0.01 to the broad based SPY ETF.
AQST has a market cap of $383.26 million. This is considered a Small Cap stock.
Last quarter Aquestive Therapeutics reported $13 million in Revenue and -$.10 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.02.
In the last 3 years, AQST stock traded as high as $6.40 and as low as $.62.
The top ETF exchange traded funds that AQST belongs to (by Net Assets): VTI, VXF, IWC.
AQST has outperformed the market in the last year with a return of +395.3%, while the SPY ETF gained +33.6%. In the last 3 month period, AQST beat the market returning +111.9%, while SPY returned +10.1%. However, in the most recent 2 weeks AQST has underperformed the stock market by returning -21.7%, while SPY returned +1.7%.
AQST support price is $3.76 and resistance is $4.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AQST stock will trade within this expected range on the day.